Guidelines for augmentation of circulating blood vome — Shock Fluid Therapy (Proceedings)
Apr 01, 2008
CVC IN WASHINGTON, D.C. PROCEEDINGS
Recognition of an ineffective circulating volume
"Preload" parameters are those which address whether or not the heart is receiving a venous return sufficient to expect reasonable forward blood flow. "Forward flow" parameters are those which address the issues of stroke volume, cardiac output, arterial blood pressure and tissue perfusion. It is the forward flow parameters that are commonly and distinctly affected by aberrations in circulating blood volume and constitute the usual tip-off that there is a problem. The column titles "hypodynamic" are typical findings in hypovolemia, but may also be associated with any version of heart failure (congestive heart failure, mitral insufficiency, aortic stenosis, pericardial tamponade) or end-stage sepsis. The column titled "hyperdynamic" might represent the findings in hypervolemia, but are also typical of early systemic inflammatory response syndrome and hyperthermia.
The usual compensatory response to hypovolemia is an increase in heart rate and peripheral vasoconstriction (pale color, prolonged capillary refill time, cool appendages, and oliguria). Diminished pulse quality (height and width of the pulse pressure wave form) is the consequence of reduced stroke volumes secondary to the reduced venous return and tachycardia. Cardiac output would be proportionately reduced, but blood pressure is usually maintained until the compensatory mechanisms can no longer compensate. Metabolic markers of inadequate tissue oxygenation include an increasing base deficit, lactate, oxygen extraction, and venous-arterial PCO2 difference, and a decreasing central venous PO2. For all parameters, the greater the deviation from normal, the greater the underlying circulatory deficit. As for all cardiovascular or metabolic parameters, no one parameter defines a circulatory deficit; collect as many as possible in order to be the most secure in your assessment.Poor forward flow parameters may be associated with hypovolemia but they may also be associated with poor heart function. In such cases it is possible to overload the heart (and cause pulmonary or systemic edema) prior to normalizing the forward flow parameters. When the forward flow parameters have not responded to a reasonable dose of fluids or if there is reason to suspect poor heart performance, fluids should be titrated to preload parameter end-points rather than forward flow parameter end-points (Table 8-1). When the preload parameters have been normalized and the forward flow parameters are still unacceptable, heart-specific therapy is indicated, such as sympathomimetic therapy if poor contractile function is suspected or pericardiocentesis if pericardial fluid is identified.
Goals of blood volume restoration therapy
General principles of fluid therapy
While circulating volume can be augmented by any fluid, there are vast differences between fluids with regard to their ability to accomplish this without harming the patient. This is partly determined by their redistribution characteristics after their administration and it is imperative to understand the physiology of fluid distribution across the vascular and cell membranes. Fluid choice is also partly determined by their solute content compared to normal blood; electrolytes, albumin, and hemoglobin concentrations cannot be allowed to get too high nor too low.
Isotonic crystalloids are commonly used to replace interstitial deficits in dehydrated patients and support circulating blood volume. Their use should be restricted in patients with interstitial edema. Artificial colloids are primarily used for blood volume and colloid osmotic pressure support and restoration. Plasma could be used for colloidal blood volume support, but this use is usually precluded by its expense. Plasma could also be used for albumin replacement, but in the face of ongoing albumin loss, this use is also limited by its expense. Plasma is, therefore, most often relegated to coagulation factor replacement. Hemoblobin products are primarily used for hemoglobin replacement in the anemic patient.